Stocks to Watch 09-12-07

XTL BIOPHARMACEUTICALS (NASD: XTLB)
"Up 40.3% on Tuesday"

Detailed Quote: http://www.otcpicks.com/quotes/XTLB.php

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of therapeutics for the treatment of neuropathic pain and hepatitis C. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of diabetic neuropathic pain. XTL is also developing several novel pre-clinical hepatitis C small molecule inhibitors. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ, London, and Tel- Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).

XTLB News:

September 10 - XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB; LSE: XTL; TASE: XTL) recently announced the initiation of a Phase IIb clinical trial of Bicifadine - a serotonin and norepinephrine reuptake inhibitor (SNRI) - for the treatment of diabetic neuropathic pain.

Bicifadine is being developed for the treatment of diabetic neuropathic pain which represents a significant unmet medical need in the rapidly growing multi-billion dollar neuropathic pain market. Bicifadine is a member of the SNRI drug class, a proven class in the treatment of diabetic neuropathic pain. Bicifadine's efficacy in reducing pain has been clearly demonstrated in over 15 clinical trials in acute pain, and its favorable safety profile has been established in over 3,000 patients. Importantly, Bicifadine has a unique ratio of reuptake inhibition of serotonin versus norepinephrine, which differentiates it from other members of the SNRI drug class.

The Phase IIb trial that was launched today is aimed at demonstrating the efficacy of Bicifadine in diabetic neuropathic pain, using a study design that is similar to the successful registration trials of Cymbalta®, a member of the SNRI class that is approved for this indication, and other approved agents for neuropathic pain.

The Phase IIb study is a randomized, double-blind, placebo-controlled study comparing 200mg 3x/day (tid) and 400mg 3x/day (tid) of Bicifadine versus placebo, with a 1:1:1 randomization between the three arms, in patients with diabetic neuropathic pain. The Phase IIb study is designed to enroll approximately 330 patients. Approximately 45 clinical centers in the United States, Europe and India will participate in the study. Following randomization, all patients will enter a 2-week titration period to allow them to gradually escalate up to their target treatment dose. This will be followed by a 12-week steady-state treatment period at the target treatment dose. The primary endpoint of the study is to compare the efficacy of each of the two active doses of bicifadine (200mg tid and 400mg tid) versus placebo in reduction of pain associated with diabetic neuropathy, at baseline (at the time of randomization) versus week 14 (week 12 of the steady-state phase). Pain will be measured based on a 24-hour pain rating using the 11-point Pain Intensity Numeric Rating Scale (formerly referred to as the LIKERT scale).

The lead investigators in the study are Dr. Andrew Boulton, M.D. and Dr. Sherwyn Schwartz, M.D. Dr. Boulton is Professor of Medicine, Division of Endocrinology, Diabetes and Metabolism, at the University of Miami and the University of Manchester, UK. Professor Boulton has been active in clinical research in diabetic neuropathy over the last 25 years and has published over 250 peer reviewed articles on the subject. He was co-chair of the committee that formulated the American Diabetes Association statement on diabetic neuropathy published in Diabetes Care in 2005. Dr. Schwartz is Chief Executive Officer and Chief Medical Officer of DGD Research, Inc. which is the largest diabetes and endocrinology practice in the United States. Dr. Schwartz has over 20 years of clinical research experience in diabetes and diabetic complications, and has participated in hundreds of clinical trials in the field.

AXIS TECHNOLOGY (OTC: AXTG)
“Up 38.4% on Tuesday”

Detailed Quote: http://www.otcpicks.com/quotes/AXTG.php

Axis Technologies Group, Inc. conducts its business through a wholly owned subsidiary, Axis Technologies, Inc., a Delaware corporation headquartered in Lincoln, Nebraska. Axis Technologies, Inc. designs, manufactures and markets a proprietary line of energy-saving and daylight harvesting electronic dimming ballasts for the commercial lighting industry. The company's target market is small to large commercial users of fluorescent lighting including office buildings, wholesale and retail buildings, hospitals, schools, and government buildings. In 2002, Underwriters Laboratory (UL) approved Axis products for sale in both the United States and Canada. The Axis Dimming/Daylight Harvesting (DDH) ballast is priced competitively and is the only daylight harvesting ballast system that can be marketed as a replacement for a standard ballast.

AXTG News:

September 11 - Axis Begins Shipping Dimming/Daylight Harvesting Ballasts to HD Supply, A Former Subsidiary of Home Depot

Axis Technologies Group, Inc. (Pink Sheets:AXTG) announced today that after receiving initial purchase orders in April 2007, the Company has begun shipping the Axis Dimming/Daylight Harvesting (DDH) Ballast to HD Supply™. HD Supply is a former subsidiary of The Home Depot, Inc. (NYSE:HD) and was sold by the company on August 30, 2007. For ten years HD Supply was considered the wholesale arm of Home Depot catering primarily to the commercial market selling to builders, contractors, government entities, industrial businesses and maintenance professionals

“We are delighted to add HD Supply to our growing list of high profile customers” said Jim Erickson, President of Axis. “We have worked hard to build market awareness of our product and now the market is responding. I believe we are in the right place at the right time with our energy saving ballast as Green initiatives continue to dominate the headlines.”

Ballasts are an electronic component that regulates voltage in fluorescent lighting. Axis Technologies Group, Inc. has developed a proprietary new ballast that focuses on expanding daylight harvesting into mainstream fluorescent lighting applications The patented Axis Dimming/Daylight Harvesting Ballast is a new technology that transforms the ballast, a once standard lighting industry staple, into a dynamic energy saving system that can reduce lighting energy costs by up to 70%--savings that is acknowledged by an increasing list of utilities across the United States and Canada offering rebates to their customers. The Axis DDH Ballast utilizes an individual photo sensor to automatically adjust the amount of electrical current flowing to the light fixture, and then dims or increases lighting in response to the amount of available sunlight that may be harvested from available windows and sunlight. The Axis DDH Ballast avoids "over-lit" conditions that increase energy costs by keeping lighting "tuned" to the desired level in a designated area.

CORCEPT THERAPEUTICS (NASD: CORT)
"Up 37.6% on Tuesday"

Detailed Quote: http://www.otcpicks.com/quotes/CORT.php

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the development of drugs for the treatment of severe psychiatric and metabolic diseases. Corcept's lead product, CORLUX, is currently in Phase 3 clinical trials for the treatment of the psychotic features of psychotic depression. The drug is administered orally to psychotic depression patients once per day for seven days. CORLUX, a potent GR-II antagonist, appears to mitigate the effects of the elevated and abnormal release patterns of cortisol seen in psychotic depression. In June 2007, Corcept Therapeutics announced positive results from its proof of concept study evaluating the ability of CORLUX to mitigate weight gain associated with olanzapine, a commonly used antipsychotic medication. The Company is in the process of fully evaluating all of the data from the study and considering its next steps. For additional information about the company, please visit www.corcept.com

CORT News:

September 11 - Corcept Therapeutics Receives FDA Notification Opening IND for CORLUX(R) for the Treatment of Cushing's Syndrome

Corcept Therapeutics Incorporated (NASDAQ: CORT) recently announced that it has received notification from the Food and Drug Administration (FDA) that the FDA has opened the Investigational New Drug application (IND) for CORLUX for the treatment of Cushing's Syndrome. CORLUX is a cortisol receptor (GR-II) antagonist..

In July 2007, the Company announced the receipt of Orphan Drug Designation for CORLUX for the treatment of Cushing's Syndrome. Drugs that receive Orphan Drug Designation obtain seven years of marketing exclusivity from the date of drug approval as well as tax credits for clinical trial costs, marketing application filing fee waivers and assistance from the FDA in the drug development process.

In the communication regarding the opening of the IND, the FDA indicated that a single study may provide a reasonable basis for the submission of a New Drug Application (NDA) for Corlux for the treatment of Cushing's Syndrome, which allows us to initiate the 50-patient open label study defined by the protocol submitted with the application for the IND. Corcept has begun qualifying potential sites for this study and expects to open the trial for enrollment late in the fourth quarter of 2007.

UNIVERSAL DETECTION TECHNOLOGY (OTCBB: UDTT)
"Up 37.5% on Tuesday"

Detailed Quote: http://www.otcpicks.com/quotes/UDTT.php

Universal Detection Technology is a developer of monitoring technologies, including bioterrorism detection devices. The Company on its own and with development partners is positioned to capitalize on opportunities related to Homeland Security. For example, the Company, in cooperation with NASA, has developed a bio-terror 'smoke' detector that detects certain biohazard substances. For more information, please visit http://www.udetection.com.

UDTT News:

September 11 - Universal Detection Technology Receives Purchase Order From the British Government

Universal Detection Technology (OTCBB:UDTT)(www.udetection.com), a developer and marketer of early-warning monitoring technologies to protect people from bioterrorism, announced recently that it has received a purchase order from the government of England. The order is for consumables and software for two of the Company's BSM-2000 anthrax detection systems previously purchased by the British Government. The order also includes point detection kits which are capable of detecting anthrax, Ricin toxin, Botulinum toxin, plague, and SEBs.

"We are very pleased to have reached this milestone. The British Government was the first customer for our BSM-2000 product line and we are excited to have received a new order from them for additional consumables and software for their systems. We are also pleased to have the opportunity to supply them with our point bioterrorism detection kits," said Jacques Tizabi, UDTT's Chief Executive Officer.

SANTA FE GOLD CORP (OTCBB: AZMN)
"Up 33.3% on Tuesday"

Detailed Quote: http://www.otcpicks.com/quotes/AMZN.php

Santa Fe Gold Corp (OTCBB: AZMN) is a U.S.-based mining and exploration company focused on acquiring and developing gold, silver, copper and industrial mineral properties. The company owns the Summit silver-gold property and a mill site and processing equipment in southwestern New Mexico; mineral lease rights to the Ortiz gold property in north-central New Mexico, believed to contain two million ounces of gold; the Black Canyon mica mine and processing facility near Phoenix, Ariz.; and a large resource of micaceous iron oxide (MIO) in western Arizona. Santa Fe Gold intends to build a portfolio of high-quality, diversified mineral assets with an emphasis on precious metals. To learn more about the company, visit www.santafegoldcorp.com.

AMZN News:

September 11 - Santa Fe Gold Corp Announces New Ticker Symbol of SFEG Effective as of September 12, 2007

Santa Fe Gold Corp (OTC Bulletin Board: AZMN), formerly Azco Mining Inc., a U.S.-based mining and exploration enterprise focused on gold, silver, copper and industrial minerals, today announced that effective September 12, 2007, its new ticker symbol will be “SFEG” for trading on the OTB Bulletin Board.

Pierce Carson, CEO, said, “Our recent name change and new ticker symbol reflect the company’s strategic objective of building a mid-tier precious metals exploration and mining company.

“We plan for production to begin initially at our Summit silver-gold property, to be followed by our Ortiz gold property. We also intend to expand our precious metals resource base, which exceeds 2 million ounces of gold, through aggressive exploration programs and acquisition of additional properties.

NABI BIOPHARMACEUTICALS (NASD: NABI)
"Up 22.9% on Tuesday"

Detailed Quote: http://www.otcpicks.com/quotes/NABI.php

Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop and, in certain areas, market products that target serious medical conditions in the areas of hepatitis and transplants, gram positive bacterial infections and nicotine addiction. We are a vertically integrated company with sales of antibodies and other biologics, including Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], a pipeline of products in various stages of development and a state-of-the-art manufacturing capability. The company operates through two strategic business units: Nabi Biologics and Nabi Pharmaceuticals. Nabi Biologics has responsibility for the company's protein and immunological products and development pipeline, including Nabi- HB. Nabi Pharmaceuticals is responsible for the NicVAX(R) (Nicotine Conjugate Vaccine) and StaphVAX(R) (Staphylococcus aureus Polysaccharide Conjugate Vaccine) development programs. For a complete list of pipeline products, please go to: http://www.nabi.com/pipeline/index.php. The company is headquartered in Boca Raton, Florida. For additional information about Nabi Biopharmaceuticals, please visit our Web site: http://www.nabi.com.

NABI News:

September 11 - Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG

Nabi Biopharmaceuticals (Nasdaq: NABI) announced Tuesday that it has entered into a definitive agreement with Biotest AG, Dreieich, Germany to sell the Nabi Biologics strategic business unit (SBU) to Biotest Pharmaceuticals Corporation for $185 million. Biotest researches and manufactures pharmaceutical, biotherapeutic and diagnostic products and has more than 1,200 employees worldwide.

Biotest has agreed to acquire the Biologics SBU's products, including Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], and other plasma business assets, including Nabi's state-of-the-art plasma protein production plant, and nine FDA-certified plasma collection centers across the U.S. The acquisition also will include certain of Nabi's Corporate Shared Services group assets and the company's Boca Raton, Florida headquarters and other facilities, as well as the assumption of certain liabilities.

'This agreement definitively puts us on the final path to a successful outcome of our strategic alternatives process,' said Dr. Leslie Hudson, Interim President and Chief Executive Officer of Nabi. 'We feel this transaction not only will realize value for Nabi shareholders but also will allow us to build on the promise of our Pharmaceuticals SBU pipeline. I am delighted that after the transaction closes our Nabi Biologics and Corporate Shared Services employees will have the prospect of a promising future with Biotest.'

'With the acquisition of Nabi Biologics, we have found the ideal complement for our European plasma protein business and have become a global player in the industry,' said Professor Dr. Gregor Schulz, Chairman of the Management Board of Biotest AG. 'We have an immediate share in the highly attractive and growing US plasma protein market and are substantially expanding our capacities, extending our product range and consolidating our clinical development portfolio.'